These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37685875)

  • 1. Identification of the HNSC88 Molecular Signature for Predicting Subtypes of Head and Neck Cancer.
    Chuang YH; Lin CY; Lee JC; Lee CH; Liu CL; Huang SH; Lee JY; Lai WS; Yang JM
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDCSP Is an Immune-Associated Prognostic Biomarker in HPV-Positive Head and Neck Squamous Carcinoma.
    Wu Q; Shao T; Huang G; Zheng Z; Jiang Y; Zeng W; Lv X
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291667
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients.
    Nan Z; Dou Y; Chen A; Wang K; Sun J; Meng Z; Neckenig M; Ai D; Liu S; Dong Z; Ma C; Cheng Y; Qu X
    Front Immunol; 2022; 13():1100417. PubMed ID: 36703967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer.
    Murphy RM; Tasoulas J; Porrello A; Carper MB; Tsai YH; Coffey AR; Kumar S; Zeng PY; Schrank TP; Midkiff BR; Cohen S; Salazar AH; Hayward MC; Hayes DN; Olshan A; Gupta GP; Nichols AC; Yarbrough WG; Pecot CV; Amelio AL
    Cancer Res Commun; 2022 Sep; 2(9):987-1004. PubMed ID: 36148399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an 8 HPV-related RNA signature as a novel prognostic biomarker for squamous cell carcinoma of the head and neck.
    Mei Z; Zhengdong L; Shupeng L; Xin Z; Lei W; Wang C
    Medicine (Baltimore); 2024 Feb; 103(6):e36448. PubMed ID: 38335428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
    Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
    Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated analysis of diagnostic, prognostic value and potential drug treatment of GSDME in head and neck squamous cell carcinoma.
    Hu R; Lu M; She L
    Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4239-4253. PubMed ID: 37204444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-methylome-derived epigenetic fingerprint as an immunophenotype indicator of durable clinical immunotherapeutic benefits in head and neck squamous cell carcinoma.
    Li R; Wen X; Lv RX; Ren XY; Cheng BL; Wang YK; Chen RZ; Hu W; Tang XR
    Cell Oncol (Dordr); 2024 Aug; 47(4):1129-1148. PubMed ID: 38315286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
    Huang J; Liang B; Wang T
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head and neck squamous cell carcinoma-specific prognostic signature and drug sensitive subtypes based on programmed cell death-related genes.
    Xu C; Xu H; Liu B
    PeerJ; 2023; 11():e16364. PubMed ID: 38025757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
    Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
    Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular classification of human papilloma virus-negative head and neck squamous cell carcinomas: Cell cycle-based classifier and prognostic signature.
    Gu H; Li T; Beeraka NM; Zheng Y; Zhang X; Song R; Zhou R; Wang X; Sukocheva O; Fan R; Liu J
    PLoS One; 2023; 18(10):e0286414. PubMed ID: 37903125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
    Sun K; Chen RX; Li JZ; Luo ZX
    Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HPV Induced Cancer Resource (THInCR): a Suite of Tools for Investigating HPV-Dependent Human Carcinogenesis.
    Salnikov M; Gameiro SF; Zeng PYF; Barrett JW; Nichols AC; Mymryk JS
    mSphere; 2022 Aug; 7(4):e0031722. PubMed ID: 35950764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptors signature reveal the head and neck squamous cell carcinoma energy metabolism phenotype and clinical outcome.
    Yao Y; Wang D; Zhang Y; Tang Q; Xu Z; Qin L; Qu Y; Yan Z
    J Gene Med; 2024 Jan; 26(1):e3605. PubMed ID: 37932968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes.
    Lee DJ; Eun YG; Rho YS; Kim EH; Yim SY; Kang SH; Sohn BH; Kwon GH; Lee JS
    Oral Oncol; 2018 Oct; 85():44-51. PubMed ID: 30220319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Complete Validation of Prognostic Gene Signatures for Human Papillomavirus-Associated Cancers: Integrated Approach Covering Different Anatomical Locations.
    Kwon EJ; Ha M; Jang JY; Kim YH
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33361419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival-related indicators ALOX12B and SPRR1A are associated with DNA damage repair and tumor microenvironment status in HPV 16-negative head and neck squamous cell carcinoma patients.
    Li J; Tang LL; Ma J
    BMC Cancer; 2022 Jun; 22(1):714. PubMed ID: 35768785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Resolution Profiling of Head and Neck Squamous Cells Carcinoma Identifies Specific Biomarkers and Expression Subtypes of Clinically Relevant Vulnerabilities.
    Zhu Y; Peng B; Luo X; Sun W; Liu D; Li N; Qiu P; Long G
    Curr Med Chem; 2024; 31(17):2431-2448. PubMed ID: 37936459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic changes of the EMT spectrum between circulating tumor cells and the tumor microenvironment in human papillomavirus-positive head and neck squamous cell carcinoma.
    Ida S; Takahashi H; Tada H; Mito I; Matsuyama T; Chikamatsu K
    Oral Oncol; 2023 Feb; 137():106296. PubMed ID: 36571985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.